BioVariance Research Services Pathway-based Pharma portfolio analyses Josef Scheiber, PhD www.biovariance.com

BioVariance - Overview Two distinct offerings rooted in the same data: • “Medical value content”-as-a-Service for Healthcare • making sense of genomic & other data IN CONTEXT as

service offering

Bio-Variance BaVarians ;)

Overview • Background • Analysis approach • Example • Outlook

Background • Patents hold a significant amount of recent,

highly relevant information • Question to answer: What targets do my

competitors publish patents for? What indication are they working on for a particular target?

• How can I use this for my efforts? • We aim for testable hypotheses that are well-

supported by data from scientific databases and the literature

Recent competitor patents provide plenty of relevant knowledge

Competitor project

own project

Patent

Leveraging competitor information for better drug understanding

Primary target of competitor compound Indication: Z

Primary target of own compound Indication: Y

Treating a disease/symptom

Consequence: Should we also look into Indication Z?

General workflow

Big Pharma A Patents published

in 2011

Manual curation

TARGET NAME

ABBREVIATION

UniProt ID

MODE OF ACTION

INDICATIONS

TYPE OF DRUG MOLECULES

CHEMICAL NATURE OF DRUG MOLECULE

Standard identifiers for basic content

General workflow

Big Pharma A Patents published

in 2011

Machine-readable description of patent content

Big Pharma B Patents published

in 2011

compare

Statistics of targets in patents • Pharma A 41 unique ID Targets, 7 of them with several patent • Pharma B 36 unique ID Targets, 16 of them with several patents • 6 Targets where both have patents (Q9UBL9; P04150; P30559;

P07550; P10275; Q9Y5N1)

A B

Pharma A (2010) Pharma B (2011)

Total patents published (for specified year) 83 103

Relevant patents 75 76

35

6

30

Comparison of indications on target-level

P04150 Treatment of inflammation and/or allergic conditions., Treatment of inflammatory and/or allergic conditions.

Treatment of inflammation related condition (e.g. asthma, rheumatoid arthritis, dermatitis, inflammatory bowel disease, transplant rejection, multiple sclerosis, chronic uveitis, or chronic obstructive pulmonary disease); mitigating bone loss associated with prednisolone treatment., Treatment of inflammation related condition (e.g. asthma, rheumatoid arthritis, dermatitis, inflammatory bowel disease, transplant rejection, multiple sclerosis, chronic uveitis, or chronic obstructive pulmonary disease); mitigating bone loss associated with prednisolone treatment.

P07550

Treatment of pulmonary disorders, e.g. chronic obstructive pulmonary disease (COPD) and asthma., Treatment and prophylaxis of diseases associated with reversible airways obstruction such as asthma, chronic obstructive pulmonary diseases (COPD) (e.g. chronic and wheezy bronchitis, emphysema), respiratory tract infection and upper respiratory tract disease (e.g. rhinitis, including seasonal and allergic rhinitis), premature labour, depression, congestive heart failure, skin diseases (e.g. inflammatory, allergic, psoriatic, and proliferative skin diseases), conditions where lowering peptic acidity is desirable (e.g. peptic and gastric ulceration) and muscle wasting disease.

Treatment of premature labor, congestive heart failure, depression, inflammatory and allergic skin diseases, psoriasis, proliferative skin diseases, glaucoma and in conditions where there is an advantage in lowering gastric acidity, particularly in gastric and peptic ulceration, chronic bronchitis and emphysema., Treatment of premature labor, congestive heart failure, depression, inflammatory and allergic skin diseases, psoriasis, proliferative skin diseases, glaucoma and in conditions where there is an advantage in lowering gastric acidity, particularly in gastric and peptic ulceration, chronic bronchitis and emphysema.

Opportunity?

Mapping into biological Pathways (here: Nature Pathway Interaction Database)

Target list T1 T2 T3

Pathway A

Pathway B

Automated mapping of target identifiers into biological pathways, each target can be a member of several pathways (exemplified with T2), thereby one can link annotations from competitor patents (like indication) to the pathways of own projects Also a combined visualization is possible

Mapping into biological Pathways (here: Nature Pathway Interaction Database)

• Pharma A: 41 unique IDs map into 116 Pathways, 64 of them with several targets (40% of pathways worked on covered by competitor)

• Pharma B: 36 unique ID Targets map into 77 Pathways, 32 of these with several targets (61% of pathways worked on covered by competitor)

• 47 Pathways where both have patents (see next slide for example)

A B 69

47

30

Comparison of indications on pathway level (in total 47 matching pathways)

Pathway Indication Patent Company A Indication Patent Company B

angiopoietinreceptor_pathway

Treatment of rheumatoid arthritis, osteoarthritis, meningitis, ischemic and hemorrhagic stroke, neurotrauma/closed head injury, stroke, endotoxemia and/or toxic shock syndrome, other acute or chronic inflammatory disease states such as the inflammatory reaction induced by endotoxin or inflammatory bowel disease, tuberculosis, atherosclerosis, muscle degeneration, multiple sclerosis, cachexia, bone resorption, psoriatic arthritis, Reiter's syndrome, gout, traumatic arthritis, rubella arthritis and acute synovitis.

Treatment of cancer.

ap1_pathway Treatment of inflammation and/or allergic conditions.,

Treatment of inflammatory disorders, autoimmune disorders (e.g., lupus), skin-inflammatory disorders, intestinal inflammatory disorders, asthma and atopic disorders, and transplant graft rejection, neurological disorders or complications due to stroke or head injury, benign or malignant neoplastic disease, carcinomas and adenocarcinoma and proliferative disorders., Treatment of inflammation related condition (e.g. asthma, rheumatoid arthritis, dermatitis, inflammatory bowel disease, transplant rejection, multiple sclerosis, chronic uveitis, or chronic obstructive pulmonary disease); mitigating bone loss associated with prednisolone treatment., Treatment of inflammatory disorders, autoimmune disorders (e.g., lupus), skin-inflammatory disorders, intestinal inflammatory disorders, asthma and atopic disorders, and transplant graft rejection, neurological disorders or complications due to stroke or head injury, benign or malignant neoplastic disease, carcinomas and adenocarcinoma and proliferative disorders., Treatment of inflammation related condition (e.g. asthma, rheumatoid arthritis, dermatitis, inflammatory bowel disease, transplant rejection, multiple sclerosis, chronic uveitis, or chronic obstructive pulmonary disease); mitigating bone loss associated with prednisolone treatment.

Opportunity?

Outlook

The right drug for the right patient at the right time & right dose is only possible

if you have the right knowledge within the right context right in place

We will further work on this!

Thank you for your attention!

josef.scheiber@biovariance.com Phone: +49 – 89 – 189 6582 – 80 Garmischer Str. 4/V 80339 Munich / Germany